KBC Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.14M | Sell |
20,408
-116
| -0.6% | -$35K | 0.01% | 464 |
|
|
2026
Q1 | $6.79M | Sell |
20,524
-327,670
| -94% | -$112M | 0.02% | 412 |
|
|
2025
Q4 | $138M | Buy |
348,194
+74,842
| +27% | +$33.1M | 0.32% | 63 |
|
|
2025
Q3 | $125M | Buy |
273,352
+79,802
| +41% | +$32.5M | 0.3% | 69 |
|
|
2025
Q2 | $63.1M | Buy |
193,550
+174,238
| +902% | +$48.2M | 0.17% | 119 |
|
|
2025
Q1 | $5.21M | Sell |
19,312
-10,714
| -36% | -$2.75M | 0.02% | 451 |
|
|
2024
Q4 | $7.07M | Buy |
30,026
+5,460
| +22% | +$1.44M | 0.02% | 432 |
|
|
2024
Q3 | $6.76M | Buy |
24,566
+9,470
| +63% | +$2.47M | 0.02% | 426 |
|
|
2024
Q2 | $3.67M | Hold |
15,096
| – | – | 0.01% | 494 |
|
|
2024
Q1 | $2.26M | Buy |
15,096
+1,187
| +9% | +$198K | 0.01% | 574 |
|
|
2023
Q4 | $2.66M | Sell |
13,909
-1,601
| -10% | -$273K | 0.01% | 564 |
|
|
2023
Q3 | $2.75M | Buy |
15,510
+1,390
| +10% | +$265K | 0.01% | 537 |
|
|
2023
Q2 | $2.68M | Sell |
14,120
-13,886
| -50% | -$2.75M | 0.01% | 560 |
|
|
2023
Q1 | $5.61M | Buy |
28,006
+21,629
| +339% | +$4.55M | 0.02% | 458 |
|
|
2022
Q4 | $1.51M | Sell |
6,377
-1,449
| -19% | -$309K | 0.01% | 644 |
|
|
2022
Q3 | $1.57M | Buy |
7,826
+172
| +2% | +$32.8K | 0.01% | 590 |
|
|
2022
Q2 | $1.12M | Buy |
7,654
+215
| +3% | +$30.5K | 0.01% | 645 |
|
|
2022
Q1 | $1.22M | Buy |
7,439
+200
| +3% | +$30.5K | ﹤0.01% | 669 |
|
|
2021
Q4 | $1.23M | Sell |
7,239
-7,610
| -51% | -$1.41M | ﹤0.01% | 690 |
|
|
2021
Q3 | $2.8M | Buy |
14,849
+827
| +6% | +$155K | 0.01% | 588 |
|
|
2021
Q2 | $2.38M | Buy |
14,022
+4,453
| +47% | +$652K | 0.01% | 632 |
|
|
2021
Q1 | $1.35M | Hold |
9,569
| – | – | 0.01% | 706 |
|
|
2020
Q4 | $1.24M | Hold |
9,569
| – | – | 0.01% | 721 |
|
|
2020
Q3 | $1.39M | Sell |
9,569
-15,159
| -61% | -$2.15M | 0.01% | 653 |
|
|
2020
Q2 | $3.66M | Buy |
24,728
+11,659
| +89% | +$1.57M | 0.02% | 449 |
|
|
2020
Q1 | $1.42M | Buy |
13,069
+2,058
| +19% | +$238K | 0.01% | 624 |
|
|
2019
Q4 | $1.27M | Buy |
11,011
+345
| +3% | +$34.4K | 0.01% | 816 |
|
|
2019
Q3 | $857K | Buy |
10,666
+2,935
| +38% | +$232K | 0.01% | 921 |
|
|
2019
Q2 | $561K | Hold |
7,731
| – | – | ﹤0.01% | 1030 |
|
|
2019
Q1 | $722K | Hold |
7,731
| – | – | 0.01% | 969 |
|
|
2018
Q4 | $564K | Hold |
7,731
| – | – | 0.01% | 904 |
|
|
2018
Q3 | $677K | Hold |
7,731
| – | – | 0.01% | 1029 |
|
|
2018
Q2 | $761K | Hold |
7,731
| – | – | 0.01% | 891 |
|
|
2018
Q1 | $921K | Buy |
7,731
+65
| +0.8% | +$8.38K | 0.01% | 806 |
|
|
2017
Q4 | $974K | Buy |
7,666
+6,719
| +710% | +$844K | 0.01% | 815 |
|
|
2017
Q3 | $111K | Hold |
947
| – | – | ﹤0.01% | 1178 |
|
|
2017
Q2 | $76K | Hold |
947
| – | – | ﹤0.01% | 1199 |
|
|
2017
Q1 | $49K | Hold |
947
| – | – | ﹤0.01% | 1282 |
|
|
2016
Q4 | $35K | Sell |
947
-21,753
| -96% | -$911K | ﹤0.01% | 1284 |
|
|
2016
Q3 | $1.54M | Buy |
22,700
+18,231
| +408% | +$1.29M | 0.02% | 641 |
|
|
2016
Q2 | $248K | Hold |
4,469
| – | – | ﹤0.01% | 1050 |
|
|
2016
Q1 | $281K | Hold |
4,469
| – | – | ﹤0.01% | 972 |
|
|
2015
Q4 | $421K | Sell |
4,469
-1,100
| -20% | -$102K | 0.01% | 837 |
|
|
2015
Q3 | $448K | Sell |
5,569
-7,552
| -58% | -$839K | 0.01% | 800 |
|
|
2015
Q2 | $1.57M | Buy |
+13,121
| New | +$1.57M | 0.02% | 616 |
|
Other funds holding ALNY
KBC Group's ALNY Position: Q2 2026 in Review
KBC Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.57% in Q2 2026, selling an estimated $35K and leaving 20,408 shares worth $6.14M. The position accounts for 0.01% of the portfolio, ranked #464.
KBC Group first reported a position in ALNY in Q2 2015 and has held it in 45 quarters since. The position peaked at $138M in Q4 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- KBC Group held 20,408 shares of Alnylam Pharmaceuticals worth $6.14M as of Q2 2026.
- KBC Group sold 116 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $35K.
- Alnylam Pharmaceuticals made up 0.01% of KBC Group's portfolio in Q2 2026, its #464 holding.
- KBC Group first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
- KBC Group's Alnylam Pharmaceuticals position peaked at $138M in Q4 2025.
- 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.